Literature DB >> 7594507

An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis.

W J Karpus1, N W Lukacs, B L McRae, R M Strieter, S L Kunkel, S D Miller.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a CD4+ T cell-mediated, inflammatory demyelinating disease of the central nervous system (CNS) that serves as a model for the human demyelinating disease, multiple sclerosis. A critical event in the pathogenesis of EAE is the entry of both Ag-specific T lymphocytes and Ag-nonspecific mononuclear cells into the CNS. In the present report we investigated the role of two C-C chemokines (macrophage inflammatory protein-1 alpha (MIP-1 alpha) and monocyte chemotactic protein-1) and a C-x-C chemokine (MIP-2) in the pathogenesis of EAE. Production in the CNS of MIP-1 alpha, but not that of MIP-2, a rodent homologue of IL-8, or monocyte chemotactic protein-1, correlated with development of severe clinical disease. Administration of anti-MIP-1 alpha, but not that of anti-monocyte chemotactic protein-1, prevented the development of both acute and relapsing paralytic disease as well as infiltration of mononuclear cells into the CNS initiated by the transfer of neuroantigen peptide-activated T cells. Ab therapy could also be used to ameliorate the severity of ongoing clinical disease. Anti-MIP-1 alpha did not affect the activation of encepahlitogenic T cells as measured by cytokine secretion, surface marker expression, and ability to adoptively transfer EAE. These results demonstrate that MIP-1 alpha plays an important role in directing the chemoattraction of mononuclear inflammatory cells in the T cell-mediated autoimmune disease, EAE.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594507

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  107 in total

1.  The CC chemokine MIP-1alpha induces a selective monocyte infiltration following intradermal injection into nonhuman primates.

Authors:  P J Didier; T J Paradis; R P Gladue
Journal:  Inflammation       Date:  1999-02       Impact factor: 4.092

Review 2.  Chemokines and central nervous system disorders.

Authors:  W J Karpus
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

Review 3.  Regulation of experimental autoimmune encephalomyelitis by chemokines and chemokine receptors.

Authors:  Adam Elhofy; Kevin J Kennedy; Brian T Fife; William J Karpus
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 4.  Slit proteins, potential endogenous modulators of inflammation.

Authors:  Necat Havlioglu; Liya Yuan; Hao Tang; Jane Y Wu
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 5.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

6.  Proinflammatory cytokine, chemokine, and cellular adhesion molecule expression during the acute phase of experimental brain abscess development.

Authors:  T Kielian; W F Hickey
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

7.  C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis.

Authors:  S Youssef; G Maor; G Wildbaum; N Grabie; A Gour-Lavie; N Karin
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

8.  C-C chemokines differentially alter interleukin-4 production from lymphocytes.

Authors:  N W Lukacs; S W Chensue; W J Karpus; P Lincoln; C Keefer; R M Strieter; S L Kunkel
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

9.  Regulatory functions of CD8+CD28- T cells in an autoimmune disease model.

Authors:  Nader Najafian; Tanuja Chitnis; Alan D Salama; Bing Zhu; Christina Benou; Xueli Yuan; Michael R Clarkson; Mohamed H Sayegh; Samia J Khoury
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

Review 10.  Chemokine receptor antagonists: overcoming developmental hurdles.

Authors:  Richard Horuk
Journal:  Nat Rev Drug Discov       Date:  2008-12-12       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.